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December 20111866 AbstractsProblems With Using a Covered Stent for Pseudoaneurysms of Autog-
enous Fistula
Stephen L. Hill, Jeffrey D. Shay, Carilion Clinic, Roanoke, Va
We have recently treated two patients with complications associated
with the use of a covered stent (Bard Fluency) for salvage of an autogenous
fistula. Both patients were elderly white females with end stage renal disease
requiring dialysis. They had successfully received brachial vein transpositions
with elevation and had been on dialysis for two to six months. In both these
individuals they had developed small pseudoaneurysms due to repetitive
sticks in the same location. They presented with persistent bleeding which
was intermittent from the pseudoaneurysms. Interventional techniques were
used to place a covered stent in one, and two overlapping stents were
placedin the other patient. This treatment was immediately successful. Both
Fig 1.
Fig 2.patients continued dialysis without incident. Over the course of several
months, however it was noticed in both patients that a small scab appeared
Ft the site of the pseudoaneurysm. In both patients these small scabs
rogressed to complete erosion of the covered metal stent through the skin.
here was no bleeding associated with the erosion, just the appearance of the
etal stents over the covered prosthetic. A surgical correction was then
erformedwith a wide dissection and undermining the surrounding tissue to
ave a two layer closure over the exposed segment of the fistula/stent.
ialysis continued uninterrupted. It will require several months to deter-
ine if this approach is successful for this problem. Interventional tech-
iques with covered stents have become a mainstay of treatment for isolated
rterial bleeding and have been quite successful. It would, therefore, only
eem logical that this technology could be applied to arterial bleeding from
n autogenous dialysis fistula. Stent placement has been used extensively for
reas of stenosis in arteriovenous fistulae and grafts, however the areas are
sually deep in the tissues and not in superficial areas. The problems with use
f covered stents in these types of situation are twofold. One, when the
leeding has occurred secondary to needle sticks, with the development of a
seudoaneurysm, the area, by definition, is very superficial with limited
verlying tissue to help with healing. The other issue which is probably more
mportant is that the anatomy and histology of a vein, even an arterialized
ein, is fundamentally different from an artery. They both have a tunica
ntima, a tunica media and a tunica adventitia but in the artery the walls are
hicker and the tunica media is much larger. The thicker walls and tunica
edia of the arteries allow ingrowth and healing. The vein wall is very thin
ith less muscle fibers, collagen fibers and elastic fibers and if close to the skin
s in both these instances the covered stent will erode through the injured
hin walled vein and skin. It would appear from these case reports that an
ccess related pseudoaneurysm of an autogenous fistula might best be served
y a combined interventional approach with a surgical approach to help
over the area and bury the vessel/stent in deeper tissue.
urrent Efficacy of Open and Endovascular Interventions for Ad-
anced Superficial Femoral Artery Occlusive Disease
hristopher J. Smolock, Javier E. Anaya-Ayala, Charudatta S. Bavare,
itul S. Patel, Jean Bismuth, Hosam F. El-Sayed, Heitham T. Hassoun,
ric K. Peden, Alan B. Lumsden, Mark G. Davies, The Methodist Hospital,
ouston, Tex
Introduction: There has been a marked paradigm shift in the treat-
ent of symptomatic femoro-popliteal disease with a shift from open to
ndoluminal therapy. The consequence of this shift in therapy is poorly
escribed. The aim of this study is to examine the clinical efficacy of this shift
n treatment strategies.
Methods: A database of patients undergoing open (OPEN) and endo-
uminal (ENDO) intervention for TASC II C and D femoro-popliteal
esions between 1990 and 2010 was retrospectively queried. Kaplan-Meier
urvival analyses were performed to assess time-dependent outcomes. Factor
nalyses were performed using a Cox proportional hazard model for time
ependent variables.
Results: 2593 limbs underwent either OPEN or ENDO treatment for
ymptomatic and anatomically advanced femoro-popliteal disease over the 20
ear period (Table). There was a 2-fold rise in endovascular interventions
etween the first and second decade. In the first decade, 80% of the interven-
ions were OPEN while in the second decade, 61% of the interventions were
NDO. There were equivalent co-morbidities in both groups and survival was
lso equivalent. Endoluminal therapy was more commonly performed on
laudicants (Table). 30-day mortality was equivalent but major morbidity was
igher in OPEN compared to ENDO. Cumulative patency was equivalent in
oth groups with a similar re-intervention rate. In contrast, clinical efficacy
freedom from recurrent symptoms, maintenance of ambulation and avoidance
f major amputation) was significantly higher in the OPEN group. The pres-
nce of critical limb ischemia, diabetes, ESRD and poor tibial runoff were
redictors of poor anatomic and functional outcomes in both groups.
Conclusions: There has been a marked shift in treatment modality for
dvanced femoro-popliteal disease with a lowering of the symptomatic
hreshold for intervention over two decades likely spurred by the ease of
NDO. Although, peri-procedural and anatomic outcomes for both proce-
ures are equivalent, it appears that open surgery continues to carry a
uperior long-term clinical efficacy.
able 1.
OPEN ENDO P value
umber limbs at risk (n) 1416 1177 –
ale gender (%) 58% 64% .05
ge 67  17 67  14 ns
laudication (%) 50% 64% .05
est pain / tissue loss (%) 50% 36%
0-day mortality (%) 2% 1.5% ns
ll-cause 30-day morbidity (%) 8% 3% .01
eintervention rate 27% 22% ns
iver year clinical efficacy (%) 91  3 68  4 .01
ive year cumulative patency (%) 72  7 74  5 ns
